Staff of the Froedtert & the Medical College of Wisconsin and members of the Pulmonary Hypertension Program and the Division of Pulmonary and Critical Care Medicine are engaged in basic science research evaluating the causes of pulmonary hypertension — research that someday may lead to better treatments for this disease. The Froedtert & the Medical College of Wisconsin Pulmonary Hypertension Program also participates in clinical research studies of new and experimental therapies that are being tested in this disease.
Current clinical studies include:
- COMPASS 3 study to evaluate the effectiveness of the drug bosentan, alone or in combination with the drug sildenafil to improve a patient’s ability to exercise
- Oral Viagra (Sildenafil) for patients being treated with Flolan®
- Oral Sitaxsentan (blocks lung vessel constriction)
Basic science research includes:
- Effects of bosentan therapy on brain natriuretic peptide (BNP) blood levels
- Genetics of Pulmonary Hypertension Genetics of Venous Thrombosis (Blood Clots)
- Eicosenoid effects in lung vessels
- Effects of high blood flow in lung vessels